FDA Okays Evolocumab Add-On for FH in Children Aged 10 and Up

The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other therapies for children 10 years of age and older with either heterozygous or homozygous familial hypercholesterolemia (FH). 

Approval was based on randomized trials of evolocumab in both types of FH, the agency notes in a statement released September 24.

The HAUSER-RCT trial included patients aged 10 to 17 years with heterozygous FH who were already on statins with or without ezetimibe. They were randomly assigned to receive monthly subcutaneous injections of evolocumab (420 mg) or placebo for 24 weeks. The results, published in the New England Journal of Medicine in August of 2020, showed an average 38% reduction in LDL cholesterol among treated patients.  

In a separate study of pediatric patients with homozygous FH aged 11-17 years, those treated with evolocumab 420 mg monthly by subcutaneous injection for 80 weeks had an average 14% reduction in LDL cholesterol compared with baseline, the release said.

Patients with a serious hypersensitivity reaction to evolocumab or its excipients must not take the drug, the FDA said. “If signs or symptoms of hypersensitivity occur, patients must stop treatment,” it notes. Common side effects in pediatric patients include nasopharyngitis, headache, oropharyngeal pain, and upper respiratory tract infection. 

Evolocumab was approved in 2015 for use in addition to diet and maximally tolerated statin therapy in adults with heterozygous and homozygous familial hypercholesterolemia or clinical evidence of atherosclerotic cardiovascular disease who require further LDL cholesterol lowering.

In 2017, the FDA approved a supplemental application for evolocumab to prevent myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. It was also approved as an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia to reduce LDL cholesterol. 

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
MCOOL for beef products introduced by South Dakota’s Dusty Johnson thumbnail

MCOOL for beef products introduced by South Dakota’s Dusty Johnson

Congressman Dusty Johnson, R-SD, has introduced the Beef Origin Labeling Accountability Act to clarify and reinstate mandatory country-of-origin labeling (MCOOL) for beef products.  South Dakota’s “lone voice” in Congress explained: “Consumers don’t know where their beef comes from. It could be South Dakota, Brazil, or Canada,” said Johnson. “U.S. producers raise better beef, and they’re not getting the
Read More
Dietary supplements for weight loss thumbnail

Dietary supplements for weight loss

Dietary supplements for weight lossMelt away fat. Lose weight naturally. Tempting claims, but do the products deliver?By Mayo Clinic Staff The promise of fast weight loss is hard to resist. But do weight-loss supplements lighten anything but your wallet? And are they safe? What are dietary supplements? Dietary supplements are sold as health aids. They're…
Read More
למרות אזהרות הרופאים, הפטור מבידוד תלמידים נכנס הבוקר לתוקף thumbnail

למרות אזהרות הרופאים, הפטור מבידוד תלמידים נכנס הבוקר לתוקף

מתווה ביטול הבידוד במערכת החינוך החל היום, לאחר החלטת הממשלה אמש לא לבטלו. אתמול קראו רופאים ומומחים למחלות זיהומיות במערכת הבריאות לבכירי המשרד לעכב את המתווה ולהמתין עם יישום המהלך. יו"ר איגוד רופאי הילדים, פרופ' צחי גרוסמן, אף התבטא: "אנחנו באיגוד מרימים דגל אדום עכשיו וממליצים לא לבטל את בידוד הילדים", והסביר את החשש מהמתווה:…
Read More
Index Of News